{
    "clinical_study": {
        "@rank": "137911", 
        "arm_group": {
            "arm_group_label": "Exemestane and cyclophosphamide", 
            "arm_group_type": "Experimental", 
            "description": "A treatment cycle is defined as 4 weeks:\nOne tablet (25 mg) of exemestane and one tablet (50 mg) of cyclophosphamide given daily by mouth until disease progression or unacceptable adverse events."
        }, 
        "brief_summary": {
            "textblock": "This phase II trial studies how well exemestane and cyclophosphamide work in treating\n      patients with estrogen receptor (ER) -positive, progesterone receptor (PR) -positive, and\n      human epidermal growth factor receptor (HER)2-negative stage IV breast cancer."
        }, 
        "brief_title": "Exemestane and Cyclophosphamide for Metastatic Breast Cancer", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Beast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane may\n      fight breast cancer by blocking the use of estrogen by the tumor cells.  Low dose\n      cyclophosphamide may also stimulate the white blood cells, including natural killer cells,\n      for instance by decreasing the suppressor (regulatory) T-cells. Giving exemestane with\n      cyclophosphamide may be an effective treatment for estrogen receptor-positive, progesterone\n      receptor-positive, and HER2-negative stage IV breast cancer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have histologically confirmed breast cancer that is ER positive and/or\n             PR positive, and HER2/neu negative and have disease that is metastatic (stage IV)\n\n               -  HER2/neu negative disease determined using commercially available/approved assay\n                  in local institutional or reference laboratory, according to American Society of\n                  Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines (IHC\n                  0-1+ or 2+ with HER2/17 ratio on FISH <= 1.8).\n\n               -  ER/PR expression performed by standard immunohistochemical assay and classified\n                  as ER and/or PR-positive according to ASCO/CAP guidelines (1-100% expression)\n\n               -  Histologic and/or cytologic confirmation of metastatic disease is encouraged\n                  whenever feasible, furthermore, if feasible, the biopsy should confirm that the\n                  metastatic tumor is ER and/or PR positive and HER2/neu negative. For patients in\n                  whom histologic biopsy confirmation and/or assessment of ER/PR/HER2 of\n                  metastatic disease is not feasible, it is required that the primary tumor be ER\n                  and/or PR-positive and HER2/neu negative.\n\n          -  Measurable disease (RECIST 1.1) or non-measurable (assessable) disease\n\n          -  Patients must have had progressive disease during at least one line of endocrine\n             therapy for metastatic disease or have recurrent disease while or within 12 months of\n             receiving adjuvant endocrine therapy. Prior treatments accepted include a\n             non-steroidal aromatase inhibitor, tamoxifen, fulvestrant or combinations.\n\n          -  Patients taking bisphosphonates for bone disease are permitted to enter the trial,\n             but their bone lesions are not considered to be assessable for response, although\n             they are assessable for progression.\n\n          -  Female or male subjects age >= 18 years.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.\n\n          -  Patients must have normal organ and marrow function as defined below:\n\n               -  absolute neutrophil count >= 1,200/mcL\n\n               -  platelets >= 100,000/mcL\n\n               -  hemoglobin >= 9g/dl\n\n               -  total bilirubin <= 2 X upper limit of normal (ULN) [unless due to Gilbert's\n                  disease]\n\n               -  AST(SGOT) <= 2.5 X ULN\n\n               -  ALT(SGPT) <= 2.5 X ULN\n\n               -  creatinine <=  1.5 X ULN\n\n          -  Patients must be able to swallow and tolerate oral medications.\n\n          -  Postmenopausal status, defined as 60 years and older, being 45 years and older and\n             having amenorrhea x 12 months or follicle stimulating hormone levels within\n             postmenopausal range, OR having undergone a bilateral oophorectomy.\n\n          -  Ability to understand and the willingness to sign a written informed consent\n             document.\n\n        Exclusion Criteria:\n\n          -  Patients may not be receiving any other investigational agents.\n\n          -  Prior treatment for breast cancer with a steroidal aromatase inhibitor; with the\n             exception of patients who were started on the combination of exemestane with\n             everolimus less than 4 weeks prior to study entry and discontinued everolimus due to\n             poor tolerability.\n\n          -  Presence of life threatening metastatic visceral disease (defined as extensive\n             hepatic involvement or symptomatic pulmonary lymphangitic spread) or uncontrolled\n             brain metastases.\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "23", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01963481", 
            "org_study_id": "S13-00761"
        }, 
        "intervention": [
            {
                "arm_group_label": "Exemestane and cyclophosphamide", 
                "intervention_name": "Exemestane", 
                "intervention_type": "Drug", 
                "other_name": "Aromasin"
            }, 
            {
                "arm_group_label": "Exemestane and cyclophosphamide", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Cytoxan", 
                    "CTX"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Exemestane"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "hormonal therapy", 
            "immunotherapy"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10016"
                }, 
                "name": "NYU Cancer Center"
            }, 
            "investigator": [
                {
                    "last_name": "Yelena Novik, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "James Speyer, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Komal Jhaveri, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Marleen Meyers, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ruth Oratz, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Sylvia Adams, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Derya Unutmaz, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Trial of Exemestane With Immunomodulatory Cyclophosphamide in ER and/or PR-positive and HER2/Neu Negative Metastatic Breast Cancer", 
        "overall_contact": {
            "email": "sylvia.adams@nyumc.org", 
            "last_name": "Sylvia Adams, MD", 
            "phone": "212-263-6485"
        }, 
        "overall_contact_backup": {
            "email": "tiffany.drumond@nyumc.org", 
            "last_name": "Tiffany Drumond", 
            "phone": "212-263-2171"
        }, 
        "overall_official": {
            "affiliation": "New York University School of Medicine", 
            "last_name": "Sylvia Adams, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The three-month period starts from first treatment day.  Evaluation of disease progression is based on Response Evaluation Criteria in Solid Tumor (RESIST) guideline version 1.1.", 
            "measure": "Percentage of patients who are progression free at 3 months", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01963481"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Evaluation of response is based on RESIST guideline version 1.1.  Response is assessed every 12 weeks.", 
                "measure": "Response rate (complete response and partial response)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Clinical benefit rate is defined as the percentage of patients who have achieved objective response or stable disease for at least 24 weeks.  Evaluation of response and disease progression is based on RESIST guideline version 1.1.  Response and progression are assessed every 12 weeks.", 
                "measure": "Clinical benefit rate", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "New York University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "New York University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}